The pivotal study highlighted WATS3D's significant impact on improving precancer detection during GERD screenings.

CDx Diagnostics, Inc., developer and provider of the WATS3D solution, today announces a substantial expansion in its insurance coverage network.

CDx Diagnostics, Inc. today announced that it has received its 400,000th WATS3D specimen. WATS3D, the company’s proprietary diagnostic platform leverages AI enabled tissue analysis and 3D imaging to identify precancerous cells in the esophagus

This was a collaborative study among gastrointestinal pathologists who have an interest and expertise in Barrett’s esophagus.

"The landmark findings highlight how our AI imaging technology can effectively transform early detection rates and empower physicians to intervene before progression to esophageal cancer.